
SureNano Science Ltd. Positions Itself in GLP-1 Obesity Drug Market
SureNano Science Ltd. is advancing GEP-44, a novel GLP-1-based peptide for obesity, leveraging its acquisition of GlucaPharm Inc. and aiming to compete with blockbuster drugs like Ozempic and Wegovy.
Read full story
























